Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Immune checkpoint blockade (ICB) therapy has significantly progressed the treatment of bladder cancer (BLCA). Multiple studies have suggested that specific genetic mutations may serve as immune biomarkers for ICB therapy. Additionally, the nuclear receptor corepressor 1 (NCOR1) gene is a new player in the field of immune tolerance and the development of immune cells. In the ICI-treated-cohort, NCOR1 mutations may be used as a biomarker to predict the prognosis of BLCA patients receiving ICIs. The overall survival (OS) of the NCOR1-mutant (NCOR1-MT) group was significantly longer than that of NCOR1-wild-type (NCOR1-WT) group (P = 0·031; HR [95%CI]: 0·25 [0·12–0·52]). In the TCGA-BLCA-cohort, compared with NCOR1-WT, NCOR1-MT was associated with known predictors of ICB therapy efficacy, such as higher tumor mutational burden (TMB), neoantigen load and the number of mutations in the DNA damage-repair pathway. In addition, NCOR1-MT tumors had highly infiltrating TILs, activated antitumor immunity, and a high expression of immune-related genes, suggesting that NCOR1 mutations may serve as a potential biomarker to guide ICB therapy in BLCA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778 · cited 1×
“Additionally, we used the ESTIMATE algorithm to calculate the stromal and immune scores and tumor purity of the TCGA-BLCA cohort (24).”
MethodThe Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870 · cited 2×
“The neoantigen load (NAL) data in The Cancer Genome Atlas Urothelial Bladder Carcinoma (TCGA-BLCA) cohort were obtained from a literature review (18).”
BackgroundMethodSelf-citationSignatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Jiang, P., Gu, S., Pan, D., Fu, J., Sahu, A., Hu, X., Li, Z., Traugh, N., Bu, X., Li, B., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0136-1 · Cited by 5,179
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · cited 1×
“Multiple studies have demonstrated that highly infiltrating TILs (such as CD8+ T cells and CD4+ T cells) are associated with improved ICI efficacy in a variety of tumors (3, 4, 6).”
BackgroundAnalysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519 · cited 1×
“Consistent with other literature (20), nonsynonymous mutations in TCGA-BLCA were used as raw mutation counts and divided by 38 Mb to quantify TMB.”
MethodMutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · cited 1×
“For instance, mutations in the interferon signaling pathway genes JAK1/2, B 2M, IFNGR1, IFNGR2, and APLNR indicate that patients with melanoma are resistant to immunotherapy (35, 36); mutations in genes related to the DDR pathway, such as POLE, POLD1, MLH1, MSH2, PMS2, MSH6, BRCA1, BRCA2, TP53, PRKDC, LIG3, RAD17, RAD…”
BackgroundBalar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199 · cited 1×
“Multiple studies have demonstrated that highly infiltrating TILs (such as CD8+ T cells and CD4+ T cells) are associated with improved ICI efficacy in a variety of tumors (3, 4, 6).”
Background
Cited by
CAMOIP: a web server for comprehensive analysis on multi-omics of immunotherapy in pan-cancer
Lin, A., Qi, C., Wei, T., Li, M., Cheng, Q., Liu, Z., Luo, P., & Zhang, J. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac129 · Cited by 152
Self-citationPotential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review
Li, Y., Zhang, C., Jiang, A., Lin, A., Liu, Z., Cheng, X., Wang, W., Cheng, Q., Zhang, J., Wei, T., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05104-y · Cited by 105
“Excessive adipocyte accumulation in the body incites stress, including endoplasmic reticulum and oxidative stress, eventually culminating in a chronic inflammatory microenvironment [183, 184].”
BackgroundSelf-citationImmunological classification of tumor types and advances in precision combination immunotherapy
Ren, X., Guo, S., Guan, X., Kang, Y., Liu, J., & Yang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.790113 · Cited by 62
“CTLA-4 inhibits the early activation and differentiation of T cells (usually in the lymph nodes), while PD-1 transmits inhibitory signals and regulates the effector function of T cells (mainly in the tumor) (19).”
BackgroundLin, A., Zhang, H., Meng, H., Deng, Z., Gu, T., Luo, P., & Zhang, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.667875 · Cited by 27
Self-citation
Metadata
- Authors
- Lin, A., Qiu, Z., Zhang, J., & Luo, P.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2021-03-08
- Volume
- 12
- Pages
- 630773-630773
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3194506780
- Cited by
- 45
- References
- 17
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer. https://app.cochat.ai/papers/10.3389/fimmu.2021.630773
- The paper
- Lin, A., Qiu, Z., Zhang, J., & Luo, P. (2021). Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2021.630773
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.